samedan logo
 
 
spacer
home > ebr > winter 2002 > realising the potential of human cells for therapy
PUBLICATIONS
European BioPharmaceutical Review

Realising the Potential of Human Cells for Therapy

Cell therapy offers the potential to revolutionise health care. Instead of taking medicines that address only the symptoms of chronic disease, cell implants and engineered tissues will be able to cure a broad range of health conditions. The potential returns, both in terms of clinical benefit and financial reward, are significant. Not only can cell therapies displace expensive medicines, they can also greatly reduce the costs of supporting patients on long-term medical regimes. This is not a theoretical proposition - cell and cell-derived therapies are already being used effectively for a variety of applications.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Will West, Product Development Director at CellFactors Dr Will West is Product Development Director at CellFactors plc, where his main focus has been on developing and commercialising SkeletexTM, a human cell-derived matrix that induces bone formation.
His scientific background is in immunology, virology and cell culture, and he completed his PhD, sponsored by Unilever (UniPath), in 1992. Following this, Dr West held a post-doctoral position at the National Institute of Biological Standards and Control, working on HIV vaccines and MHC proteins. Dr West subsequently worked at Procter & Gamble, responsible for product and claims development in a number of health care therapeutic areas. He has an MBA from London Business School.

spacer
Dr Will West
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Ultra slim and ultra quick


More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement